Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 18, 2024 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers

Research on breast, colorectal, head and neck, and testicular cancersNovel downregulation of WNK1 and Wnt signaling KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals,...
February 16, 2022 09:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Metastatic Uveal Melanoma Abstract for Oral Presentation at 2022 International Society of Ocular Oncology (ISOO) Congress

KNOXVILLE, TN, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 for the treatment of...
February 08, 2022 05:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Systemic Administration Abstract at American Association for Cancer Research (AACR) Annual Meeting 2022

KNOXVILLE, TN, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on systemic administration of investigational cancer immunotherapy PV-10 (rose...
November 16, 2021 08:15 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers

AGOURA HILLS, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,...
November 04, 2020 10:30 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination

Notice of Allowance received for combination of RedHill’s novel orally-administered investigational drugs, opaganib and RHB-107, for treatment of solid tumor cancers; patent expected to extend IP...
March 17, 2020 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

PV-10® Abstract Previously Accepted for Presentation at Terminated American Association for Cancer Research (AACR) Annual Meeting 2020

KNOXVILLE, TN, March 17, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today said that data from ongoing research into investigational lysosomal-targeting cancer immunotherapy PV-10 (rose bengal...
February 13, 2015 10:18 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Closing of Public Offering of Its American Depository Shares

TEL-AVIV, Israel, Feb. 13, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...